Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) to Host “Global IP Strategy Forum for Bio-Pharma” on October 27

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association will hold the “Global IP Strategy Forum for Bio-Pharma” on October 27 at 2:00 p.m. in the 4th-floor auditorium of the Pharmaceutical Association Building in Seoul.

The forum has been organized in response to the rapid globalization of the bio-pharmaceutical industry, as intellectual property (IP) issues such as overseas licensing agreements, M&A, investment, and patent disputes have emerged as key factors in corporate competitiveness. Through this event, the Association aims to strengthen the IP risk management capabilities of Korean bio-pharmaceutical companies and explore practical strategies for addressing these challenges.

As the importance of end-to-end IP management grows—from early-stage drug development and IP strategy formulation to contractual issues, dispute resolution, and financing—the forum will serve as a venue for discussing practical solutions based on domestic and international case studies.

The program will open with Patent Attorney Yoon Sun-young of Kim & Chang presenting on “Practical IP Issues in Overseas Licensing Agreements,” introducing key clause design strategies based on real contract examples. Attorney Choi Sang-kyun, also from Kim & Chang, will follow with a session on “Essential IP Management Strategies in Overseas M&A and Investments,” covering IP rights succession procedures and due diligence checklists.

Patent Attorney Yoon Kyung-ae of Yulchon LLC will deliver a presentation on “Building an IP Portfolio and Patent Dispute Strategies for Global Expansion,” analyzing major global patent dispute types and case-specific response strategies. Foreign Attorney Tae Hun Lee of LITIG Equity Partners will introduce the use of Third Party Funding (TPF) as a tool for Korean companies to manage the financial and procedural risks they face in overseas disputes.

A panel discussion will follow under the theme “IP Strategies and Challenges for Korean Companies in the Global Bio-Pharma Market.” The discussion will be chaired by Professor Joon-Hyug Chung of Seoul National University School of Law and will feature panelists from Kim & Chang, Yulchon LLC, LITIG Equity Partners, Yuhan Corporation, and OMNI Bridgeway, a leading global TPF funding group. The panel will discuss Korean companies’ experiences in managing IP risks during overseas co-development projects, as well as case studies of TPF utilization in the global bio-pharma sector, exploring diverse approaches to building effective global IP strategies.

A KPBMA representative commented,

“As Korean companies expand their technological collaboration and investment in the global market, the ability to systematically manage IP risks in advance is becoming increasingly critical. This forum will serve as a valuable opportunity to provide practical guidance for companies in developing effective global collaboration and dispute response strategies.”